Headquartered in New York, NY Fiscal year ends December NYSE: PFE pfizer.com
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide.
**Business structure**
Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions:
- Pfizer U.S. Commercial Division
- Pfizer International Commercial Division
- Global Hospital and Biosimilars Division
**Product portfolios**
- **Primary Care:** Eliquis, the Prevnar family, Nurtec ODT/Vydura, Comirnaty, Abrysvo, Paxlovid and FSME-IMMUN/TicoVac.
- **Oncology:** Ibrance, Padcev, Xtandi, Lorbrena, Inlyta, Braftovi/Mektovi, Adcetris, Orgovyx, Tukysa, Bosulif, Elrexfio, Talzenna and Tivdak.
- **Specialty Care:** the Vyndaqel family, Xeljanz, Zavicefta, Enbrel, Octagam, BeneFIX, Cresemba, Genotropin and Cibinqo.
- **Hospital and Biosimilars (formed in 2026):** off-patent sterile injectables and biosimilars such as Retacrit, Ruxience, Zirabev, Inflectra and Sulperazon.
**Other operations and revenue sources**
- Pfizer CentreOne provides contract manufacturing and active pharmaceutical ingredient sales.
- Revenue comes from product sales, alliance revenues (e.g., Eliquis, Xtandi, Orgovyx) and royalties.
- The U.S. accounts for roughly two-thirds of sales.
**Strategy**
Pfizer is shifting away from declining COVID-19 products toward launched and acquired medicines, including those from the Seagen acquisition. It is investing in oncology, obesity, immunology and next-generation vaccine programs. It is also executing an enterprise-wide cost realignment and de-levering its balance sheet. Updated
Pfizer is outrunning its COVID hangover: Paxlovid sales fell 63%, yet full-year revenue guidance rose to $62 billion to $64 billion. That is the seventh straight quarter of topping EPS expectations.
Pfizer cleared $30 for the first time in a year, closing at $30.52 and topping its October 22 peak by 0.33%. The $173.9 billion drugmaker was trading near $23 twelve months ago.
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know…
A pre-tax 401(k) hides a tax bill nobody has paid yet, and the way you settle it can swing the cost by six figures. One timing choice, plus a December 31 deadline,…
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.…
Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that…
Pre-Market Stock Futures: Futures are mixed this Friday morning, with the Dow Jones trading lower, but Nasdaq futures are higher as AI stocks catch a bid after the big post-election rally…
When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim…
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.52, up 5% in afternoon trading, as the…
Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they…
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the…
Four stocks are paying out billions in dividends that their cash flows can barely support, and the gap between what investors expect and what the business can actually deliver keeps widening. Before…
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has…
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real…
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
Some of the fattest dividend yields on the market right now come from stocks that have already cut their payouts once, and three more may be quietly building toward the same moment.…
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide. **Business structure** Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions: - Pfizer U.S.
24/7 Wall St.'s 12-month price target for PFE is $33.67, rated Buy. The Wall Street consensus target is $29.72. PFE price prediction →
